Renalytix Laboratories

Michael Donovan Ph.D., M.D. joined Renalytix, Inc in 2018 and serves as the Chief Medical Officer. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid–based assays and coupled mathematical applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Along with his clinical duties, Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.

In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of Aureon Biosciences, Inc, Chief Medical Officer of MetaStat, Inc., Chief Medical Officer of Exosome Diagnostics, Inc. where he was a laboratory and medical director responsible for clinical assay development, validation and implementation as well as overseeing the execution of several clinical trials and authored multiple publications. He was also the Chief Medical Officer of Vigilant Biosciences where he was responsible for the development and monitoring of multiple European trials and a multi-site FDA study.

Dr. Donovan earned a B.S. in Zoology from Rutgers University, a Master of Science in Endocrinology and a Ph.D. in Cell and Developmental Biology with Post–Doctoral studies at Harvard Medical School. After completing his Pediatric Fellowship at Children’s Hospital, he transitioned to an Assistant Professor in the department of pathology at Harvard Medical School. He earned his M.D. from the University of Medicine and Dentistry of New Jersey.

Anne E. Tebo, Ph.D., D(ABMLI) is the Laboratory Director of Renalytix Inc. Dr. Tebo has over 15 years experience in clinical and diagnostic immunology including test development, validation, implementation, and oversight.

Dr. Tebo received her doctoral degree from the Eberhard Karls Universität in Tübingen, Germany and completed postdoctoral training in immunology in the Department of Microbiology at the University of Alabama at Birmingham. She continued her training with a clinical immunology fellowship in the Department of Pathology at the University of Utah School of Medicine and is board certified in medical laboratory immunology by the American Board of Medical Laboratory Immunology (ABMLI).

She is a member of several professional societies, including the Association of Medical Laboratory Immunologists (AMLI), American Society of Microbiology (ASM), American Association of Clinical Chemists (AACC) and the American College of Rheumatology (ACR).

Baljit (BJ) Singh is Head of Clinical Laboratory Operations for Renalytix. He is responsible for all clinical lab operations activities across the company.

Prior to joining Renalytix in February 2020, Mr. Singh held various leadership roles at Quest Diagnostics, a worldwide provider of IVD diagnostics, where he helped accelerate growth and led various laboratories. Before joining Quest Diagnostics, he held science and technical operations roles with ARUP Laboratories and Labcorp.

Mr. Singh received an MBA from University of Utah’s David Eccles School of Business and a bachelor’s degree in Clinical Lab Science from the University of Nebraska Medical Center. He is certified in Six Sigma methodologies. He is fluent in Hindi, Punjabi and loves to be outdoors.